You are about to be taken to a third-party site. The content on this site is for informational use only. Immunocine does not endorse any of the information, products, or services on third-party sites, and no information on third-party sites should be construed as an endorsement or recommendation of specific Immunocine products. By clicking on the link below, you consent to be directed to external material.Proceed Cancel
Effective Date: 01/01/22
Last Reviewed: 01/01/23
Immunocine (Criogenia Y Biotecnologia S.A.P.I. DE C.V.), the Immunocine partnering medical officials, facilities, hospitals, personnel, and labs are all officially registered, licensed, and certified with the Mexican government.
Immunocine Treatment Disclaimer
The Immunocine treatment is designed to turn on, educate, and optimize a cancer patient’s immune system to recognize and attack the patient’s cancer, a natural biological phenomenon that usually occurs when threats, including cancers, become present. In accordance with Mexican law, this treatment is offered as part of a palliative care protocol to patient’s deemed to have limited treatment options by medical professionals, and is an attempt to improve quality of life.
Increased lifespan, including remission, are possible once a patient’s immune system has been educated and activated by the Immunocine Dendritic Cell Treatment to target and fight a patient’s cancer, but is not a guarantee. Every patient is different and results will vary and have been varied in the patients treated to date.
The Immunocine treatment is an autologous (a.k.a. “self”) cell therapy made using the patient’s own cancer and own immune cella, and subsequently administered to the patient by board certified medical professionals. All final cell products are tested for contaminations and analyzed for quality control measures per patient per injection. All final cell products are stored and administered according to professional standards and scientific and medical understandings based on existing research. No drugs or supplements are made by Immunocine.
All patient Dendritic Cell Treatments are made following the standard operating procedures of the Dendritic Cell technology in FDA-approved clinical trials Nos. NCT04157127 and NCT04552886.
Though we provide our services in Mexico, we herein provide a disclaimer regarding any disclosures made on this website to US citizens as per FTC requirements.
In accordance with the FTC guidelines concerning use of endorsements and testimonials in advertising, please be aware of the following:
Immunocine is not responsible for any of the opinions or comments posted to our site. The Immunocine website and ads are not a forum for testimonials, however testimonials can be provided as a means for existing or ex-patients to share their experiences with one another, or with prospective patients assessing Immunocine as a treatment option. To prevent abuse, all official testimonials appear after they have been reviewed by Immunocine. All testimonials are made voluntarily and none of the ex-patients are paid for such testimonials.
Additionally, the FDA has not yet evaluated or clinically validated these claims.
Website Information Disclaimer
Limitation of Warranties
The medical and scientific information on this website is provided “as is” without any representations or warranties, express or implied. Immunocine and its website property Immunocine.com makes no representations or warranties in relation to the medical or scientific information on this website that cannot be substantiated by peer-reviewed publications, medical records, or other professional documentation.
Though optimism is reasonable, no results can be guaranteed on a patient-per-patient basis. While the Immunocine team will attempt to keep all information current, the Immunocine team does not promise to update this information in real time, therefore, some information may be out of date.
No Medical Advice Online or in Print
This website contains general information about medical conditions and treatments. The information is not medical advice, and should not be treated as such. Though the material on the website and in print describe the scientific concepts, data, and merits of the Dendritic Cell Treatment approach while also describing the potential of positive outcomes, it should not be construed as a replacement for a patient’s medical care or the advice of your personal physician or oncologist.
If you think you may be suffering from any medical condition you should seek immediate medical attention. Never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information on this website.
Professional and Medical Assistance
You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider. Though the Immunocine team will oversee patient medical care as it pertains to this Dendritic Cell Treatment, it should not be interpreted that primary and/or sole care of the patient should fall to the Immunocine doctors. If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.
Clinical Trial Priority
It is understood that the treatment being offered by Immunocine in Cancun is synonymous to the Dendritic Cell protocol employed in clinical trials NCT04157127 and NCT04552886, but is under the permissions of palliative care in Mexico.
If a patient has a diagnosable cancer that may allow for eligibility in one of the open FDA clinical trials, they will be referred to the appropriate US oversight team to gauge candidacy. Only if not eligible may a patient pursue treatment with Immunocine.